Vande Velde
Koen Vande Velde, Mortsel BE
Patent application number | Description | Published |
---|---|---|
20160112603 | SYSTEM AND METHOD FOR REGULARIZING AN INK MODEL FOR A COLOR DEVICE - A method including the steps of selecting an n-ink model for a color device, for transferring a set of colorant values in colorant space to a set of color values in color space; selecting a printer characteristic of the n-ink model, wherein the printer characteristic indicates the regularity of the n-ink model; evaluating, for the n-ink model, a set of one or more values and/or ranges for the printer characteristic, thus determining the regularity of the n-ink model; and modifying the n-ink model such that the modified n-ink model is regular, if, based on the evaluation, the n-ink model was not regular. | 04-21-2016 |
Vincent Vande Velde, New York, NY US
Patent application number | Description | Published |
---|---|---|
20090130145 | VACCINE - The invention provides an attenuated rotavirus population comprising a single variant or substantially a single variant which is defined by a nucleotide sequence encoding at least one of the major viral proteins designated as VP4 and VP7. The invention particularly provides a rotavirus population designated as P43. The invention further provides a novel formulation for a rotavirus vaccine which is in the form of a quick dissolving tablet for immediate dissolution when placed on the tongue. | 05-21-2009 |
Vincent Vande Velde, Rixensart BE
Patent application number | Description | Published |
---|---|---|
20120237547 | LIVE ATTENUATED ROTAVIRUS VACCINE FOR ORAL ADMINISTRATION - The invention provides liquid rotavirus formulations that are suitable for oral administration to human infants. In particular the invention provides pharmaceutical compositions and vaccines, comprising a rotavirus antigen, a sugar and a carboxylate wherein said formulation has a pH of between pH 5.0 and pH 8.0 and comprises no phosphate or less than 5 mM phosphate. The invention also provides methods of preparing said rotavirus formulations and use thereof in the prevention or treatment of rotavirus associated diseases in humans. | 09-20-2012 |